Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity. The company has been reducing its overall debt, with a net debt standing at Rs. 1,020 crores as of September 2025. There is no indication of any immediate plans to raise fresh capital via equity or additional debt. CAPEX expansions, including a 6,000 metric tons capacity increase, are being funded internally as per the discussion. The focus appears to be on organic growth through capacity expansion, product launches, and operational efficiency.

Any current/future capex/capital investment/strategic investment?

Privi is undertaking a CAPEX plan split into three phases; part one of Phase-1 was completed ahead of schedule. The ongoing portion of Phase-1 is expected to complete by the end of FY 2025-26, increasing production capacity from 48,000 to 54,000 metric tons. An additional 6,000 metric tons capacity expansion is poised to be commercialized by December 2025, effective from January 2026. Privi Biotechnology, a wholly-owned subsidiary focused on R&D via biotechnology, is working on commercializing products and plans a demonstration plant within 15 months. The company aims to leverage outputs from

Future growth expectations in sales/revenue/volumes?

Privi Speciality Chemicals aims to achieve Rs. 5,000 crores in revenue and Rs. 1,000 crores in EBITDA over the next 3-4 years, representing more than 2x growth. Expected CAGR in revenue is upward of 20%, consistent with the company's past two decades' growth. Growth will be driven by internal metrics including capacity expansion (from 48,000 MT to 54,000 MT by January 2026) and introduction of new specialty products. Volume growth was ~17% in the first half, with a price increase contributing about 8%-10%. Majority of growth comes from a mix of volume-driven and high specialty chemicals produc

Future growth expectations in earnings/operating earnings/profits/EPS?

Privi Speciality Chemicals aims for a revenue target of Rs. 5,000 crores and EBITDA of Rs. 1,000 crores over the next 3-4 years, implying more than 2x growth. The company plans a CAGR of over 20% in revenues, consistent with its performance over the last two decades. EBITDA margin guidance is maintained at 24%-26%, including state incentives, supported by operational excellence and value addition from byproducts. Volume growth and new product introductions are expected drivers of revenue expansion; capacity to increase from 48,000 MT to 54,000 MT by January 2026. Working capital cycle improvem

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders for Privi Speciality Chemicals Limited. However, it is indicated that contract renewals occur in the October to December period, and the company expects to maintain its sales run rate through these contracts. Management emphasizes strong demand across product categories with no noted decline in recent months. Capacity expansion (additional 6,000 MT) is expected to be operational by end of December 2025, facilitating increased order fulfillment from January 2026 onwards. The company is confident abou

Privi Speci.Q2 FY26

Privi Speci. Q2 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,424P/E: 39.9Market Cap: ₹14.0K Cr

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Privi Speciality Chemicals aims to achieve Rs. 5,000 crores in revenue and Rs. 1,000 crores in EBITDA over the next 3-4 years, representing more than 2x growth.
Expected CAGR in revenue is upward of 20%, consistent with the company's past two decades' growth.
Growth will be driven by internal metrics including capacity expansion (from 48,000 MT to 54,000 MT by January 2026) and introduction of new specialty products.
Volume growth was ~17% in the first half, with a price increase contributing about 8%-10%.
Majority of growth comes from a mix of volume-driven and high specialty chemicals products.
New product pipeline includes about 10 specialty molecules with high value and margins, plus other products mainly for existing customers in F&F and some diversification into pharma and electronics.
De-bottlenecking processes provide incremental growth but majority growth expected from new products.

Margin guidance

Category 3

Privi Speciality Chemicals aims for a revenue target of Rs. 5,000 crores and EBITDA of Rs. 1,000 crores over the next 3-4 years, implying more than 2x growth.
The company plans a CAGR of over 20% in revenues, consistent with its performance over the last two decades.
EBITDA margin guidance is maintained at 24%-26%, including state incentives, supported by operational excellence and value addition from byproducts.
Volume growth and new product introductions are expected drivers of revenue expansion; capacity to increase from 48,000 MT to 54,000 MT by January 2026.
Working capital cycle improvements and CAPEX plans underpin margin sustainability.
Margins and earnings growth are expected to benefit from backward integration, sustainability focus, and reduced product dependency by diversifying the product portfolio.
The company anticipates steady contract renewals without revenue softness.

See what Privi Speci. management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or planned fundraising through debt or equity.
The company has been reducing its overall debt, with a net debt standing at Rs. 1,020 crores as of September 2025.
There is no indication of any immediate plans to raise fresh capital via equity or additional debt.
CAPEX expansions, including a 6,000 metric tons capacity increase, are being funded internally as per the discussion.
The focus appears to be on organic growth through capacity expansion, product launches, and operational efficiency.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Privi Speciality Chemicals Limited.
However, it is indicated that contract renewals occur in the October to December period, and the company expects to maintain its sales run rate through these contracts.
Management emphasizes strong demand across product categories with no noted decline in recent months.
Capacity expansion (additional 6,000 MT) is expected to be operational by end of December 2025, facilitating increased order fulfillment from January 2026 onwards.
The company is confident about growth from both de-bottlenecking and new products, selling mainly to existing customers, implying a healthy and growing order pipeline.
No specific quantitative order book figures or pending order details are disclosed in the call transcript.

See what Privi Speci. management said on order book — free account, 30 seconds.

Capex plans

Yes

Privi is undertaking a CAPEX plan split into three phases; part one of Phase-1 was completed ahead of schedule.
The ongoing portion of Phase-1 is expected to complete by the end of FY 2025-26, increasing production capacity from 48,000 to 54,000 metric tons.
An additional 6,000 metric tons capacity expansion is poised to be commercialized by December 2025, effective from January 2026.
Privi Biotechnology, a wholly-owned subsidiary focused on R&D via biotechnology, is working on commercializing products and plans a demonstration plant within 15 months.
The company aims to leverage outputs from Privi Biotech for the parent company's growth, aligned with the 5K revenue vision.
State incentives for CAPEX investments from Maharashtra (15 years) and Gujarat (7 years) governments support strategic investment sustainability.
The joint venture with PRIGIV is ramping up with expected meaningful contributions in the coming years.

Track Privi Speci. — get its next earnings analysis in your feed

How does Privi Speci. rank vs peers in ?

Pro feature

ThisPrivi Speci.

Rev 2Mar 3

See where Privi Speci. sits in See which companies these are, and every other name in the sector.Open rankings

What Privi Speci.'s management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →